Roivant

Roivant is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies, founded by Vivek Ramaswamy. History Vivek Ramaswamy founded Roivant in 2015. Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas. This strategy expanded to include developing earlier stage drug candidates and platform technologies. Roivant is a parent company to over a dozen subsidiaries ranging from Immunovant, a majority-owned public company focused on autoimmune diseases, to privately held Dermavant Sciences, a commercial-stage company focused on medical dermatology. Roivant also develops healthcare technologies through its business unit Roivant Health. Roivant built and launched Datavant, which allows healthcare institutions to share data, and was merged with Coix to become a $7 billion company. Roivant's technology portfolio also includes Lokavant, which integrates clinical trial data to identify and mitigate risks in pharmaceutical development. In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. As of 2019, Roivant had over forty investigational drugs in development in fourteen therapeutic areas across its family of companies.  At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its ownership stake in five of its subsidiaries: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, which now sit under Sumitovant Biopharma. The deal included the option for Sumitomo to acquire up to six additional subsidiaries.